JP2021513552A5 - - Google Patents

Info

Publication number
JP2021513552A5
JP2021513552A5 JP2020543742A JP2020543742A JP2021513552A5 JP 2021513552 A5 JP2021513552 A5 JP 2021513552A5 JP 2020543742 A JP2020543742 A JP 2020543742A JP 2020543742 A JP2020543742 A JP 2020543742A JP 2021513552 A5 JP2021513552 A5 JP 2021513552A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
drug
ibutamorene
ghs
Prior art date
Application number
JP2020543742A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513552A (ja
JPWO2019161025A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/017964 external-priority patent/WO2019161025A1/en
Publication of JP2021513552A publication Critical patent/JP2021513552A/ja
Publication of JP2021513552A5 publication Critical patent/JP2021513552A5/ja
Publication of JPWO2019161025A5 publication Critical patent/JPWO2019161025A5/ja
Priority to JP2023221157A priority Critical patent/JP2024028337A/ja
Priority to JP2025129927A priority patent/JP2025179056A/ja
Withdrawn legal-status Critical Current

Links

JP2020543742A 2018-02-14 2019-02-14 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物 Withdrawn JP2021513552A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023221157A JP2024028337A (ja) 2018-02-14 2023-12-27 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物
JP2025129927A JP2025179056A (ja) 2018-02-14 2025-08-04 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862630361P 2018-02-14 2018-02-14
US62/630,361 2018-02-14
PCT/US2019/017964 WO2019161025A1 (en) 2018-02-14 2019-02-14 Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023221157A Division JP2024028337A (ja) 2018-02-14 2023-12-27 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物

Publications (3)

Publication Number Publication Date
JP2021513552A JP2021513552A (ja) 2021-05-27
JP2021513552A5 true JP2021513552A5 (https=) 2022-02-21
JPWO2019161025A5 JPWO2019161025A5 (https=) 2022-02-21

Family

ID=67620042

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020543742A Withdrawn JP2021513552A (ja) 2018-02-14 2019-02-14 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物
JP2023221157A Pending JP2024028337A (ja) 2018-02-14 2023-12-27 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物
JP2025129927A Pending JP2025179056A (ja) 2018-02-14 2025-08-04 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023221157A Pending JP2024028337A (ja) 2018-02-14 2023-12-27 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物
JP2025129927A Pending JP2025179056A (ja) 2018-02-14 2025-08-04 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の治療のための組成物

Country Status (10)

Country Link
US (3) US20210059993A1 (https=)
EP (3) EP4623929A3 (https=)
JP (3) JP2021513552A (https=)
KR (2) KR20200121308A (https=)
CN (2) CN118453597A (https=)
AU (2) AU2019222736B2 (https=)
BR (1) BR112020016613A2 (https=)
CA (1) CA3088177A1 (https=)
EA (1) EA202091464A1 (https=)
WO (1) WO2019161025A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113646327A (zh) * 2019-03-29 2021-11-12 综合医院公司 用于治疗肝脏疾病的ghrh或其类似物
WO2022059946A1 (ko) * 2020-09-18 2022-03-24 서울대학교 산학협력단 비알코올성 지방간염 및 간 섬유화의 치료를 위한 약학적 조성물
KR20220132312A (ko) 2021-03-23 2022-09-30 한국과학기술원 간세포의 IFN-γR1 매개 지질생성작용 억제를 통한 비알코올성 지방간 질환의 치료 방법
KR20250107210A (ko) * 2022-11-03 2025-07-11 루모스 파마, 인크. 이부타모렌의 압축형 경구 제형
WO2025193784A1 (en) * 2024-03-12 2025-09-18 Lumos Pharma, Inc. Pharmaceutical formulations for maintaining lean muscle mass during weight loss treatment
WO2025217521A1 (en) * 2024-04-12 2025-10-16 Jnana Therapeutics Inc. Treating chronic kidney disease with a combination of a slc6a19 inhibitor and a glp-1 agonist
CN119405782A (zh) * 2025-01-06 2025-02-11 山东大学 胰岛素样生长因子结合蛋白-1在制备治疗非酒精性脂肪性肝病药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US20070123470A1 (en) * 2003-10-24 2007-05-31 Wladimir Hogenhuis Enhancement of growth hormone levels with a dipeptidyl peptidase IV inhibitor and a growth hormone secretagogue
JP2007532495A (ja) * 2004-04-07 2007-11-15 ガストロテック・ファルマ・アクティーゼルスカブ グレリン欠乏を治療するための分泌促進薬の使用
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
BR112017004708A2 (pt) * 2014-09-12 2017-12-05 Tobira Therapeutics Inc terapia de combinação de cenicriviroc para o tratamento de fibrose
US20180360846A1 (en) * 2015-09-16 2018-12-20 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
WO2019008554A1 (en) * 2017-07-06 2019-01-10 Conte Anthony METHOD FOR ORAL TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE

Similar Documents

Publication Publication Date Title
JP2021513552A5 (https=)
US11938124B2 (en) Combination therapy for treatment of cancer
CN101374523B (zh) 用于治疗糖尿病的二肽基肽酶抑制剂
JP5827706B2 (ja) 併用療法においてヒストンデアセチラーゼ阻害剤を使用し、バイオマーカーをモニタする方法
TWI412366B (zh) 二肽基肽酶抑制劑之週投與方法
RU2384333C2 (ru) Применение флибансерина для лечения предменструальных и иных сексуальных расстройств у женщин
NO342004B1 (no) 2-[6-(3-amino-piperidin-1-yl)-3-metyl-2,4-diokso-3,4-dihydro-2H-pyrimidin-1-ylmetyl]-4-fluor-benzonitril for anvendelse som et medikament for behandling av diabetes, cancer, en autoimmun sykdom eller HIV infeksjon
US11357777B2 (en) Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH)
TWI842924B (zh) Gpr119致效劑及dpp-4抑制劑的藥物組合及藥物套組
TW200932249A (en) Combination therapy comprising SGLT inhibitors and DPP4 inhibitors
AU2022308121B2 (en) Combination therapy for treatment of liver diseases
RU2020109881A (ru) Агонисты рецепторов glp-1/глюкагона в лечении жировой болезни печени и стеатогепатита
TW201208702A (en) Combination therapy for treating cancer comprising an IGF-1R inhibitor and an Akt inhibitor
JP2018519340A5 (https=)
JP2021522247A5 (https=)
CN110637022A (zh) 可作为流感病毒复制抑制剂的吡咯并嘧啶衍生物
JPWO2019161025A5 (https=)
JP2023507364A (ja) インテグリン阻害剤を使用する肝疾患の治療の組み合わせ
TWI845975B (zh) 用於治療肝臟疾病的聯合治療
JP2005503391A5 (https=)
RU2818562C2 (ru) Комбинированная терапия агонистами gpr119 и ингибиторами dpp-4
US20250367218A1 (en) Methods of treating metabolic disorders and combination products for use in the same
US20230028715A1 (en) Il-31 modulators for treating fxr-induced pruritis
JP2019524860A5 (https=)
RU2022104049A (ru) Комбинированное лечение заболеваний печени агонистами fxr